Cosmo Pharmaceuticals:
FDA Allowance of IND application for CB-03-10
Cosmo Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has allowed the Investigational New Drug (IND) application for its new chemical entity CB-03-10 with androgen receptor (AR) and glucocorticoid (GR) receptor antagonist properties, so that it can initiate a phase I clinical trial in tumor bearing patients to evaluate safety, pharmacokinetics and pharmacodynamic activity.